Related by context. All words. (Click for frequent words.) 72 Investigational 71 Biologic License Application BLA 71 IND submission 70 Premarket Approval PMA 70 Biologic License Application 69 Marketing Authorisation Application 69 Premarket Approval Application 68 supplemental biologics 68 Investigational Device Exemption 68 BLA filing 67 Biologics License Application BLA 67 Marketing Authorization Application 67 Marketing Authorisation Application MAA 66 CIP TRAMADOL ER 66 FDA Approvable Letter 66 Master File DMF 66 Biologics License Application 65 Orathecin 65 Files Investigational 65 Marketing Authorization Application MAA 65 APF# NDA 65 rolling Biologics License 65 supplemental Biologics License Application 65 IND CTA 64 INDs 64 Drug Submission 64 FOLOTYN ® 64 severe hypercholesterolemia 64 IND enabling 64 PMA submission 64 Marketing Approval PMA 64 BLA submission 64 FDA approvable letter 64 Zenvia ™ 64 Premarket Notification 64 Market Approval PMA 64 midstage trials 63 sNDA submission 63 Investigational Device Exemption IDE 63 Phase Ib study 63 submit Biologics License 63 MAA submission 63 Biological License Application 63 Phase III Clinical Trial 63 PrevOnco 63 Voraxaze 63 CLIA waiver 63 New Drug IND 63 BRILINTA 63 balsalazide tablet 63 apricitabine ATC 62 Phase 2a clinical trials 62 Phase IIb clinical trials 62 pivotal bioequivalence 62 phase IIa clinical 62 CRMD# 62 Phase lll 62 Application BLA 62 Phase IIb III 62 Approvable letter 62 Stedesa 62 registrational 62 ANDA abbreviated 62 OMAPRO ™ 62 BRIM3 62 Submits Supplemental 62 Luveniq 62 sBLA 62 Pivotal Phase III 62 Files IND 62 LymphoStat B TM 62 application sNDA 62 Cloretazine ® 61 Surfaxin lucinactant 61 phase IIb clinical 61 Contrave NDA 61 Zenvia Phase III 61 phase Ib clinical 61 Completes Patient Enrollment 61 phase IIa 61 PROGENSA R 61 XOMA 3AB 61 ANDA Abbreviated New 61 PIX# trial 61 PF # [002] 61 M Enoxaparin 61 Corlux 61 Submits Investigational 61 NYSE Amex PTN 61 PDE4 inhibitor 61 Cutanea Life Sciences 61 JOULFERON 61 trastuzumab DM1 T DM1 61 Phase IIa trial 61 oral ridaforolimus 61 Civacir 61 Initiates Enrollment 61 ATL# [001] 61 k Premarket Notification 61 PNP inhibitor 61 FDA Investigational Device 61 PANVAC VF 61 Fx #A 61 acyclovir Lauriad R 61 Pre IND 61 Hematide ™ 61 CDP# 61 hoFH 61 ADVANCE PD 61 Spiegelmer ® 61 NDA submission 61 Phase #b/#a clinical 61 eprodisate KIACTA TM 61 Linjeta TM 60 tiapamil 60 Phase IIa clinical trials 60 Pfizer maraviroc 60 AMPAKINE CX# 60 Fentanyl TAIFUN R 60 Phase IIa trials 60 IND 60 preclinical toxicology 60 molecular imaging radiopharmaceutical 60 phase IIb trial 60 ISO Vorin TM 60 orphan designation 60 Phase IIB 60 Clinical Trial Application 60 KRYSTEXXA TM pegloticase 60 Junovan TM 60 Glybera R 60 Phase III Clinical Trials 60 Iluvien ® 60 Allovectin 7 60 Premarket Approval 60 Generx ™ 60 NasdaqGM SPPI 60 Personalized Immunotherapy 60 Phase Ib clinical 60 candidates Dyloject TM 60 alogliptin 60 Phase #b/#a 60 Mutual Recognition Procedure 60 Initiates Phase II 60 Surfaxin LS 60 FDA Accepts 60 histamine dihydrochloride 60 LibiGel NDA 60 Biomarker Study 60 k premarket 60 SILENOR 60 oral methylnaltrexone 60 investigational humanized monoclonal antibody 60 Panzem R 60 Anturol TM 60 LEVADEX TM 60 Phase IIIb clinical 60 lorcaserin NDA 60 HepeX B 60 VIVITROL ® 60 recombinant biopharmaceutical 60 Supplemental Biologics License Application 60 Presents Positive Preclinical 60 Vertex hepatitis C 60 OLpur TM H2H 60 Phase 2b clinical trials 60 indiplon capsules 60 HIV integrase inhibitor 60 ONCONASE R 60 DPX Survivac 60 virus HCV protease inhibitor 60 Intermezzo ® NDA 60 submitted Marketing Authorisation 60 StaphVAX R 60 Omigard 59 non nucleoside HCV 59 Kynapid 59 Dyloject TM 59 investigational pan BCR 59 FDA Complete Response 59 JZP 59 Velaglucerase Alfa 59 SYCREST 59 NASDAQ CXSP announced 59 ANDA containing 59 TQT study 59 Risperidone Oral Solution 59 rALLy trial 59 casopitant 59 Act PDUFA date 59 entity NCE 59 candidate REP# 59 Hematide ™ peginesatide 59 registrational trial 59 non nucleoside inhibitor 59 NasdaqGM NTEC today 59 Ceplene TM 59 IV acetaminophen 59 OvaRex ® MAb 59 intravenous acetaminophen 59 UCB Pharma SA 59 Phase IIb trials 59 SURFAXIN 59 Xcytrin R 59 Arzerra TM 59 Phase 1a clinical 59 SPARLON 59 Solzira 59 Biologics License Applications 59 SinuNase ™ 59 Complete Response 59 Submits Response 59 Oracea TM 59 PLK1 SNALP 59 Initiates Clinical 59 DASISION 59 Successfully Completes Phase 59 Zingo TM 59 granted Ortec 59 ORE# 59 Hedgehog antagonist 59 subsidiaries visit http:/www.apricusbio.com 59 testosterone gel LibiGel 59 Alvesco R 59 ASONEP TM 59 Initiate Phase 59 Nasdaq IDRA 59 GLP toxicology studies 59 PDUFA Date 59 Pafuramidine 59 including eniluracil ADH 59 Phase Ib II 59 New Drug Application 59 NADiA ProsVue 59 Announces Tentative Approval 59 Oncoscience AG 59 HDAC Inhibitor 59 Marketing Authorization Applications 59 Vilazodone 59 Acetavance TM 59 IMA# 59 Preotact 59 RNAi Therapeutic 59 PDX pralatrexate 59 Drug Applications ANDAs 59 Applications ANDA 59 SCIB1 59 Aloxi Injection 59 Phase III psoriasis 59 immunotherapeutic vaccine 59 zolpidem tartrate sublingual tablet 59 reslizumab 59 Gentamicin Surgical Implant 59 Drug Application 59 BLP# Liposome Vaccine 59 Inc. OTCBB ALRX 59 InterfeRx 59 Dacogen injection 59 GLP toxicology 58 ANDAs abbreviated 58 Oral Calcitonin 58 omacetaxine mepesuccinate 58 Expression Genetics 58 vinorelbine emulsion 58 SNS# T 58 zileuton CR 58 IL# PE#QQR 58 Safinamide 58 CEQ# 58 GRAS notification 58 ALN PCS 58 Submits IND 58 Vion Pharmaceuticals 58 ruxolitinib 58 Fast Track Status 58 submitted Biologics License 58 Omapro 58 Begins Dosing 58 Market Authorization Application 58 Eniluracil 58 Nabi HB Intravenous 58 dose escalation clinical 58 Receives Orphan Drug Designation 58 Biologics Licensing 58 LibiGel ® 58 LEVADEX ™ 58 IND Application 58 candidate deforolimus 58 NDA resubmission 58 confirmatory Phase 3 58 pixantrone NDA 58 ospemifene 58 website www.celsion.com 58 liver resection surgeries 58 KRYSTEXXA TM 58 Valtropin 58 compound INCB# 58 Exelbine NDA 58 Troxatyl 58 confirmatory pivotal 58 phase Ib 58 ANDAs 58 Application MAA 58 markets HP Acthar 58 initiated Phase Ib 58 ABL inhibitor 58 Hedgehog Pathway Inhibitor 58 Expedited Review 58 Inc. OTCBB SYBD 58 Approvable Letter 58 midstage clinical 58 Patient Enrollment 58 Elagolix 58 Initiates Phase III 58 Therapeutic Competitors companiesandmarkets.com adEgemonye 58 Soliris TM eculizumab 58 NASDAQ CLSN 58 miRNA therapeutics 58 ENRICH trial 58 Zensana 58 confirmatory Phase III 58 PROVENGE sipuleucel T 58 Accelerated Approval 58 Nasdaq PGNX today 58 RIGScan ™ 58 ponatinib 58 Onco TCS 58 Roflumilast 58 NEBIDO R 58 assigned PDUFA 58 lucinactant 58 vinflunine 58 PEARL SC 58 Exherin TM 58 Phase III TRIST 58 CB2 selective receptor agonist 58 adecatumumab MT# 58 Mycograb 58 Phase IIb Trial 58 Phase 2b Clinical Trial 58 successfully commercialize Iluvien 58 Paragraph IV certifications 58 SUTENT ® 58 Albugon 58 ZEGERID Chewable Tablets 58 Plexxikon proprietary 58 alvimopan 58 TLK# 58 Viviant 58 GATTEX TM 58 generation purine nucleoside 58 PREOS R 58 Friedreich Ataxia FRDA 58 LHRH antagonist 58 Davanat 58 Receives Milestone Payment 58 Phase Ib IIa 58 Submits Biologics License Application 58 PHX# 58 Annamycin 58 Simulect 58 refractory chronic lymphocytic 58 UPLYSO 58 POSIDUR TM ELADUR TM 58 HepeX B TM 58 Orphan Drug status 58 Prodarsan R 58 SPL# Gel vaginal microbicide 58 NitroMist TM 58 brentuximab 58 NDA Submission 58 Lenocta TM 58 Onalta ™ 58 SUCCEED trial 58 Onrigin 58 Orazol 58 ENTEREG ® 58 Omigard TM 58 glucokinase activator 58 Addrenex 58 investigational protease inhibitor 58 Onconase 57 vemurafenib 57 Receives Approvable Letter 57 CUSTOM III 57 outlicensed 57 Velac 57 Loramyc ™ 57 ARISE Phase III 57 Ixempra 57 Guanilib 57 RANK Ligand inhibitor 57 ORBIT II 57 tafamidis 57 sitaxsentan sodium 57 Aryplase 57 anticancer compound 57 Bionutrics 57 Complete Response letter 57 ANTEGREN 57 generation URAT1 inhibitor 57 Rhucin ® 57 SNT MC# 57 ThermoDox ® clinical 57 liprotamase 57 Pharmos pipeline 57 JAK inhibitor 57 faropenem medoxomil 57 Evoltra TM 57 MONOVISC 57 Nasdaq CLSN 57 IDE Investigational Device Exemption 57 Investigational Oral 57 Fast Track designations 57 Somatuline R Autogel R 57 KRN# 57 exemption IDE 57 Phase III confirmatory 57 Stavzor 57 Esbriet pirfenidone 57 Solorel 57 OvaRex R 57 MK #B 57 elotuzumab 57 FIRMAGON R 57 ZaBeCor 57 QRxPharma 57 RSR# 57 SFDA approval 57 ZEVALIN ® 57 OMP designation 57 Perflubutane Polymer Microspheres 57 STEDESA 57 Orphan Drug Status 57 oral taxane 57 Intarcia 57 ALN HPN 57 Orphan Drug designation 57 Pivotal Trial 57 Pegloticase 57 Presents Positive 57 Frova ® 57 IgG1 monoclonal antibody 57 ICA # 57 histone deacetylase HDAC inhibitor 57 sodium Injection 57 Allovectin 7 r 57 Marketing Authorisation 57 HCV protease inhibitor 57 Stimuvax R 57 Urocidin 57 Immune Globulin Human 57 ongoing Phase 1b 57 Firazyr 57 NASDAQ TARG 57 NASDAQ ARRY 57 Testosterone MDTS ® 57 Nasdaq OPTR 57 Fast Track Designation 57 Phase 1b clinical trials 57 Neurodex TM 57 investigational atypical antipsychotic 57 Kamada AAT 57 IIa trial 57 JAK2 Inhibitor 57 compound ISA# 57 Huntexil 57 Reports Preclinical Data 57 Bazedoxifene 57 Phase 2b study 57 TMC# [002] 57 CIMZIA r 57 Biopartners 57 Ventrus 57 TELINTRA R 57 pralatrexate injection folate analogue 57 tramiprosate Alzhemed TM 57 sNDA 57 Ketotransdel 57 novel histone deacetylase 57 Fast Track designation 57 systemic Phase 1b 57 Requip XL 57 Circ Pharma 57 midstage studies 57 Evoltra R 57 Trobalt 57 brentuximab vedotin SGN 57 OvaDx 57 MAGE A3 ASCI 57 transmucosal delivery system 57 RxKinetix 57 Curaxin CBLC# 57 Preos 57 ZEGERID Capsules 57 NASDAQ CGEN announced 57 Uvidem 57 Submits NDA 57 miconazole Lauriad R 57 Oglemilast 57 Oxytrex TM 57 BLOOM DM 57 Febuxostat 57 Hematide TM 57 mGluR2 positive 57 Zebinix R 57 Phase IIb 57 Valortim TM 57 Phase 2a clinical 57 TRX1 57 VitiGam 57 RIGScan 57 ORAL Sync 57 Keppra ® XR 57 Phase III clinical 57 Protexia ® 57 Urocidin TM 57 Pivotal Study 57 Phase IIa clinical 57 Aurora kinase inhibitor 57 CCR5 antagonist 57 Initiate Clinical Trial 57 Clevudine 57 License Application 57 carcinogenicity study 57 NYSE Amex HEB 57 PDUFA date 57 Lucanix R 57 RhuDex 57 Phase IIa 57 Taiho Pharmaceutical 57 License Option Agreement 57 Pirespa 57 evaluating satraplatin 57 Pivotal Phase 57 NASDAQ PGNX 57 Maribavir 57 Centralized Procedure 57 Nasdaq SNSS 57 PREOS 57 Nasdaq EPCT 57 R#/MEM 57 Release Capsules 57 aurora kinase 57 ixabepilone 57 Celgene Thalomid 57 opioid induced bowel dysfunction 57 AZILECT R 57 Subpart E 57 Drug Applications INDs 57 Rhucin R 57 Hsp# Inhibitor 57 ACCLAIM II 57 Orthopedic Advisory Panel 57 product candidate Lpathomab 57 Loramyc R 57 PREGNANT Study 57 Chimigen TM 57 PDUFA Prescription Drug 56 novel oral anticoagulant 56 selective androgen receptor modulator 56 intravenous methylnaltrexone 56 Fixed Dose Combination 56 Ercole Biotech 56 DC Bead 56 mitogen activated ERK kinase 56 APEX PD 56 TRO# 56 Phase 2a Trial 56 peginesatide 56 seliciclib CYC# 56 Nasdaq OSCI 56 approvable letters 56 APEX AMI trial 56 Patient Enrolment 56 Apricus Bio 56 Initiates Clinical Trial 56 NASDAQ BDSI 56 Nasdaq VRTX 56 Orphan Status 56 postapproval 56 Fodosine 56 vilazodone 56 CIP Fenofibrate 56 ACOMPLIA R 56 FlutiformTM 56 Phase IIa Clinical Trial 56 GTC NASDAQ GTCB 56 PI3K/Akt pathway inhibitor 56 candidate epratuzumab 56 dalbavancin 56 Dalbavancin 56 Arimoclomol 56 phase III isavuconazole 56 lomitapide 56 Tramadol ER 56 CHDI Foundation 56 ITAX 56 Pirfenidone 56 SinuNase TM 56 investigational oral hepatitis C 56 multicenter Phase III 56 TELINTRA 56 TBC# 56 SPRYCEL ® 56 rALLy clinical trial 56 HuMax TAC 56 CONBRIZA 56 Granted Orphan Drug 56 Staphylococcus aureus Polysaccharide Conjugate 56 BioDelivery Sciences 56 Receives Tentative FDA 56 candidate brentuximab vedotin 56 Inc. Nasdaq SEPR 56 ALTROPANE R 56 CHMP recommendation 56 Unit Dose Budesonide 56 thorough QT 56 AMEX DDD 56 PSN# [002] 56 Akela Pharma 56 Abstral ® 56 ocular formulation 56 Genasense ® oblimersen 56 oral salmon calcitonin 56 Nasdaq HALO 56 AAG geldanamycin analog 56 MorphoSys proprietary 56 NVA# 56 HCV polymerase 56 trastuzumab DM1 56 MEK inhibitor 56 investigational antiplatelet agent 56 Roche OTC RHHBY 56 AERx iDMS 56 oral prodrug 56 Nasdaq TARG 56 NASDAQ AVNR 56 IND Filing 56 IV APAP 56 Tarvacin TM 56 candidate AP# 56 generic Copaxone 56 Nasdaq PHRM 56 TSX DND 56 Tarceva TM 56 Rhucin ® recombinant 56 intranasal formulation 56 ONGLYZA ™ 56 phase 2a 56 Raptiva R 56 ISENTRESS raltegravir 56 HCV NS5B polymerase 56 FDA Accelerated Approval 56 MKC# MT 56 CVac 56 Selective Electrochemical Tumor Ablation 56 placebo controlled Phase 56 Nasdaq DVAX 56 bicifadine 56 multicenter Phase II 56 ATryn R 56 oxymorphone ER 56 Archexin 56 Cutanea 56 Nebido 56 Phase III Pivotal 56 Vicriviroc 56 Nasdaq IDRA today 56 acyclovir Lauriad ® 56 ADVEXIN p# therapy 56 LUMINATE 56 HCV polymerase inhibitor 56 inhaled formulation 56 Phase III randomized controlled 56 SWX SPPN 56 Sanvar R 56 Pimavanserin 56 Zalbin 56 Phase 1b clinical 56 Diamyd ® 56 DAVANAT ® 56 Gendux 56 PROPEL trial 56 REVIVE Diabetes 56 Evoltra ® 56 faropenem 56 mertansine 56 Camvia 56 Phase IIb Clinical Trial 56 CUSF application 56 Prednisporin TM 56 LUNESTA TM 56 targeted radiotherapeutic 56 Nasdaq CYCC Nasdaq CYCCP 56 sNDAs 56 OTCBB PYTO 56 Evoltra 56 KIF6 Genotyping Assay 56 CIP ISOTRETINOIN 56 candidate AQ4N 56 Milestone Payment From 56 Hatch Waxman Amendments 56 include Phenoptin TM 56 rxRNA 56 phase IIb 56 sumatriptan injection 56 multicenter Phase 56 NEUGENE R 56 Tanespimycin 56 ELADUR ™ 56 Debiopharm SA 56 Commences Phase 56 deforolimus 56 torezolid phosphate 56 NUEDEXTA ™ 56 Phenoptin 56 Polyphenon ® E 56 budesonide MMX Phase III 56 Metformin GR 56 Phase IIIb study 56 please visit http:/www.atherogenics.com 56 VITAL Trial 56 Ridaforolimus 56 Cellegesic 56 Emezine 56 Nasdaq CADX 56 molecular imaging pharmaceuticals 56 GSK# [002] 56 NASDAQ CRTX 56 Aegerion 56 Drug Submission NDS 56 lintuzumab SGN 56 ATL/TV# 56 RIGScan CR 56 Prestara 56 BiDil XR 56 mGluR5 negative 56 Initiated Phase 56 ThermoDox R 56 PRECISE trial 56 Tykerb lapatinib 56 Troxatyl TM 56 PROSTASCINT R 56 Inc. Nasdaq VVUS 56 Phase IIB clinical 56 Neo Kidney Augment ™ 56 MOVIPREP R 56 Crofelemer budesonide foam 56 Kosan dependence 56 Drug Candidate 56 HGS# 56 TRANSDUR Bupivacaine 56 apaziquone 56 Romidepsin 56 Virulizin R 56 Bicifadine 56 Dr. Damaj 56 nonclinical studies 56 LAF# 56 alemtuzumab MS 56 proprietary transdermal patch 56 Aflibercept 56 KNS # 56 VivaGel ™ 56 TOCOSOL Paclitaxel 56 Prosaptide 56 randomized controlled Phase 56 Inc. NASDAQ BPAX 56 Decentralized Procedure 56 tramiprosate ALZHEMED TM 56 BLAs 56 novel trazodone formulation 56 CLIRS trial 56 Marketing Authorizations 56 nasal calcitonin product 56 Augment ™ 56 Drug Eluting Stent System 56 VALSTAR 56 Meets Primary Endpoint 56 aerosolized AAT 56 MKC# MKC# PP 56 HFA MDI 56 NASDAQ ENMD 55 preclinical efficacy 55 blood thinner prasugrel 55 rALLy 55 Receives CE Marking 55 Tesmilifene 55 ATL# [002] 55 ALN VSP Phase 55 Nivestim 55 prGCD 55 Zegerid OTC 55 developed preclinically 55 SIX RO ROG 55 Locteron ® 55 Nasdaq SPPI 55 ProLindac TM 55 sirtuin modulators 55 Arzerra ofatumumab 55 Commence Phase 55 intravenous AAT 55 Anidulafungin 55 Phase 1b Clinical Trial 55 Saforis 55 Tocosol Paclitaxel 55 subcutaneous formulation 55 Barr ANDA 55 Nasdaq PPHM 55 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 55 Loramyc TM 55 #D#C# 55 PNT# 55 RenaZorb TM 55 Angiocept 55 Augment Injectable 55 forodesine 55 Awarded Qualifying Therapeutic 55 fidaxomicin Phase 3 55 Chemical Entity NCE 55 QNEXA 55 Phase 2b Trial 55 Deferiprone 55 Adventrx 55 NuroPro ® 55 EndoTAG TM -1 55 Vascular Wrap TM 55 ULTRASE 55 NuroPro R 55 Ampligen r 55 AeroLEF TM 55 EGS# 55 Ixabepilone 55 ALN HTT 55 silodosin 55 Phase III 55 ALVESCO R 55 HepaGam B 55 Orphan Drug designations 55 Marketing Authorization 55 ZOLINZA 55 treat opioid induced 55 TKB# 55 dasatinib Sprycel ® 55 Mepact 55 phase IIb study 55 T Pred 55 Randomized Double blind 55 investigational hepatitis B 55 ongoing Phase IIIb 55 NEBIDO 55 Cimzia TM 55 Phase III clinical trials 55 MAb therapy 55 ANDA filings 55 Ozarelix 55 Zenvia TM 55 CAPHOSOL R 55 ATryn ® 55 Resubmission 55 EVIZON TM 55 Completes Enrollment 55 Zemiva TM 55 OMNARIS HFA 55 phase IIb III 55 Ceflatonin ® 55 Alzhemed TM 55 Restanza 55 Panzem 55 NASDAQ OPTR 55 ChemGenex Pharmaceuticals Limited 55 ofatumumab HuMax CD# 55 confirmatory clinical 55 maribavir 55 vivo toxicology 55 Shigamabs R 55 Entereg alvimopan 55 Nasdaq NPSP announced 55 Anavex #-# 55 Phase Ib 55 BEMA Fentanyl 55 PrevOnco ™ 55 Pruvel 55 Sphingomab TM 55 ZURICH AFX Novartis AG 55 Paragraph IV 55 Prodarsan 55 Demonstrates Significant 55 CERVARIX R 55 Alogliptin 55 MethyPatch 55 drug Mylotarg 55 R#/MEM # 55 Tranzyme Pharma 55 SILENOR ™ 55 huC# DM4 55 Presents Preclinical Data 55 Phase 2b trial 55 Ereska 55 Earns Milestone Payment 55 cinacalcet HCl 55 Initiates Phase 2b 55 RNAi Therapeutics 55 receptor tyrosine kinase inhibitor 55 iii GTx 55 Receives Orphan Drug 55 placebo controlled Phase III 55 Panzem ® 55 SPD# 55 generation calcineurin inhibitor 55 BRIM2 55 Nasdaq ENCY 55 Cintredekin Besudotox 55 Inc. AMEX YMI 55 Virium 55 Initiate Phase III 55 lexidronam injection 55 novel peptides 55 REMOXY R 55 COSIRA trial 55 APTIMA HPV assay 55 Novolimus 55 Nasdaq IDIX 55 BrachySil TM 55 Phase 2a trial 55 GTC recombinant form 55 Orphan Designation 55 highly purified pasteurized 55 candidate Zenvia 55 Kyowa Kirin 55 Cloretazine 55 Nasdaq GNTA 55 vitro dissolution 55 Urokinase 55 Argatroban 55 CancerVax Corporation 55 AMD# [002] 55 NOXXON 55 Qualified Therapeutic Discovery 55 SAR# [004] 55 pseudobulbar affect PBA 55 Phase 1b trial 55 InvaGen 55 Immunotherapeutic 55 antibody MAb 55 anti CD3 monoclonal 55 eCTD format 55 lorcaserin Phase 55 Phase 2a Study 55 Trofex 55 OTCBB NVDL 55 topically applied SEPA 55 website http:/www.celsion.com 55 Supernus 55 % uracil topical 55 Phase III registrational 55 Ambrisentan 55 & LSE GLPG 55 ganetespib 55 ACUROX 55 Restanza TM 55 randomized Phase IIb 55 inhaled AAT 55 methylnaltrexone 55 atacicept 55 Liprostin 55 Pivotal Clinical Trial 55 TRANSDUR Sufentanil 55 candidate CRLX# 55 Urocortin 2 55 S OMX GEN 55 Phase III Trial 55 fluvoxamine maleate 55 Levoleucovorin 55 Lisofylline LSF 55 Fortigel 55 Q#IR 55 Galenea 55 NASDAQ NRGN 55 Ocrelizumab 55 ENLIGHT 55 Nasdaq BDSI 55 EvaMist TM 55 novel therapeutic antibodies 55 ELADUR TM 55 Augment TM 55 initiate Phase IIb 55 Onyx Pharma 55 Luvox CR 55 Phase 2b clinical 55 APEX AMI 55 FRDA 55 NASDAQ AVEO 55 Trastuzumab DM1 55 OTCQX QRXPY 55 Vivecon 55 midstage clinical trials 55 OncoVex